Drug intelligence / Profile preview

68Ga-PSMA-33

Development stage: Phase 1
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

68Ga-PSMA-33 is a novel radiopharmaceutical designed as a Prostate-Specific Membrane Antigen (PSMA) targeted probe for Positron Emission Tomography/Computed Tomography (PET/CT) imaging. It is being investigated for its safety and efficacy in the early diagnosis of prostate cancer. The drug targets PSMA, a protein that is significantly overexpressed (up to 1000 times higher) in 90-95% of prostate cancers, making it an attractive target for diagnostic imaging. 68Ga-PSMA-33 is administered intravenously and has shown good uptake in prostate cancer cell lines and animal studies.

Other names: 68Ga-labeled PSMA-33

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on 68Ga-PSMA-33.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 68Ga-PSMA-33.

Explore the full profile